Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
374 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016', provides an overview of the Metastatic Renal Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Metastatic Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Renal Cell Carcinoma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma - The report reviews pipeline therapeutics for Metastatic Renal Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Metastatic Renal Cell Carcinoma therapeutics and enlists all their major and minor projects - The report assesses Metastatic Renal Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Metastatic Renal Cell Carcinoma Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Metastatic Renal Cell Carcinoma Overview 10 Therapeutics Development 11 Pipeline Products for Metastatic Renal Cell Carcinoma - Overview 11 Pipeline Products for Metastatic Renal Cell Carcinoma - Comparative Analysis 12 Metastatic Renal Cell Carcinoma - Therapeutics under Development by Companies 13 Metastatic Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 17 Metastatic Renal Cell Carcinoma - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Unknown Stage Products 21 Metastatic Renal Cell Carcinoma - Products under Development by Companies 22 Metastatic Renal Cell Carcinoma - Products under Investigation by Universities/Institutes 25 Metastatic Renal Cell Carcinoma - Companies Involved in Therapeutics Development 26 Acceleron Pharma, Inc. 26 Amgen Inc. 27 Argos Therapeutics, Inc. 28 Astellas Pharma Inc. 29 Bayer AG 30 Bionomics Limited 31 Bionovis SA 32 Bristol-Myers Squibb Company 33 Cellceutix Corporation 34 Celldex Therapeutics, Inc. 35 Cerulean Pharma, Inc. 36 Dr. Reddy's Laboratories Limited 37 EirGenix Inc. 38 Eisai Co., Ltd. 39 Eli Lilly and Company 40 Exelixis, Inc. 41 Gene Techno Science Co., Ltd. 42 Genor BioPharma Co., Ltd. 43 Immune Design Corp. 44 Immunicum AB 45 Incyte Corporation 46 Mabion SA 47 MedImmune, LLC 48 Merck & Co., Inc. 49 Merck KGaA 50 Millennium Pharmaceuticals Inc 51 Mycenax Biotech Inc. 52 NewLink Genetics Corporation 53 Novartis AG 54 Oncobiologics, Inc. 55 Ono Pharmaceutical Co., Ltd. 56 Panacea Biotec Limited 57 Peloton Therapeutics, Inc. 58 Pfizer Inc. 59 Prima BioMed Ltd. 60 Rexahn Pharmaceuticals, Inc. 61 Richter Gedeon Nyrt. 62 Seattle Genetics, Inc. 63 Sevion Therapeutics, Inc. 64 Syndax Pharmaceuticals Inc 65 Taiwan Liposome Company, Ltd. 66 Tocagen Inc. 67 TVAX Biomedical, Inc. 68 Tyrogenex, Inc. 69 Metastatic Renal Cell Carcinoma - Therapeutics Assessment 70 Assessment by Monotherapy Products 70 Assessment by Combination Products 71 Assessment by Target 72 Assessment by Mechanism of Action 80 Assessment by Route of Administration 87 Assessment by Molecule Type 89 Drug Profiles 92 AGS-16C3F - Drug Profile 92 avelumab - Drug Profile 93 bevacizumab biosimilar - Drug Profile 98 bevacizumab biosimilar - Drug Profile 100 bevacizumab biosimilar - Drug Profile 101 bevacizumab biosimilar - Drug Profile 102 bevacizumab biosimilar - Drug Profile 103 bevacizumab biosimilar - Drug Profile 104 bevacizumab biosimilar - Drug Profile 105 bevacizumab biosimilar - Drug Profile 106 bevacizumab biosimilar - Drug Profile 107 bevacizumab biosimilar - Drug Profile 108 bevacizumab biosimilar - Drug Profile 109 BNC-105 - Drug Profile 110 cabozantinib s-malate - Drug Profile 115 capmatinib - Drug Profile 133 CDX-014 - Drug Profile 136 Cellular Immunotherapy for Metastatic Renal Cell Carcinoma - Drug Profile 137 Cellular Immunotherapy for Metastatic Renal Cell Carcinoma and Melanoma - Drug Profile 138 crizotinib - Drug Profile 139 CRLX-101 - Drug Profile 146 dalantercept - Drug Profile 157 durvalumab - Drug Profile 161 emibetuzumab - Drug Profile 171 entinostat - Drug Profile 173 flucytosine ER + vocimagene amiretrorepvec - Drug Profile 180 G-305 - Drug Profile 187 IMP-321 - Drug Profile 189 INCAGN-1876 - Drug Profile 193 Intuvax - Drug Profile 195 ipilimumab - Drug Profile 201 KM-3174 - Drug Profile 209 lenvatinib mesylate - Drug Profile 220 LY-2510924 - Drug Profile 231 Monoclonal Antibody Conjugate to Target G250 Antigen for Renal Cell Carcinoma - Drug Profile 233 nivolumab - Drug Profile 234 Orellanine - Drug Profile 262 panobinostat - Drug Profile 263 pazopanib hydrochloride + pembrolizumab - Drug Profile 271 pembrolizumab - Drug Profile 272 PT-2385 - Drug Profile 303 radium Ra 223 dichloride - Drug Profile 305 Recombinant Protein for Oncology - Drug Profile 314 rocapuldencel-T - Drug Profile 315 RX-0201 - Drug Profile 321 sapanisertib - Drug Profile 325 SGN-CD70A - Drug Profile 328 Small Molecules to Inhibit SCD1 for Metastatic Renal Cell Carcinoma - Drug Profile 329 SNX-5422 - Drug Profile 330 SVN-002 - Drug Profile 332 TLC-388 - Drug Profile 333 trebananib - Drug Profile 335 TVI-Kidney-1 - Drug Profile 339 varlilumab - Drug Profile 340 X-82 - Drug Profile 346 Metastatic Renal Cell Carcinoma - Dormant Projects 349 Metastatic Renal Cell Carcinoma - Discontinued Products 354 Metastatic Renal Cell Carcinoma - Product Development Milestones 355 Featured News & Press Releases 355 Appendix 369 Methodology 369 Coverage 369 Secondary Research 369 Primary Research 369 Expert Panel Validation 369 Contact Us 369 Disclaimer 370
List of Tables
Number of Products under Development for Metastatic Renal Cell Carcinoma, H2 2016 15 Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H2 2016 16 Number of Products under Development by Companies, H2 2016 18 Number of Products under Development by Companies, H2 2016 (Contd..1) 19 Number of Products under Development by Companies, H2 2016 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H2 2016 21 Comparative Analysis by Late Stage Development, H2 2016 22 Comparative Analysis by Clinical Stage Development, H2 2016 23 Comparative Analysis by Early Stage Development, H2 2016 24 Comparative Analysis by Unknown Stage Development, H2 2016 25 Products under Development by Companies, H2 2016 26 Products under Development by Companies, H2 2016 (Contd..1) 27 Products under Development by Companies, H2 2016 (Contd..2) 28 Products under Investigation by Universities/Institutes, H2 2016 29 Metastatic Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2016 30 Metastatic Renal Cell Carcinoma - Pipeline by Amgen Inc., H2 2016 31 Metastatic Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H2 2016 32 Metastatic Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H2 2016 33 Metastatic Renal Cell Carcinoma - Pipeline by Bayer AG, H2 2016 34 Metastatic Renal Cell Carcinoma - Pipeline by Bionomics Limited, H2 2016 35 Metastatic Renal Cell Carcinoma - Pipeline by Bionovis SA, H2 2016 36 Metastatic Renal Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 37 Metastatic Renal Cell Carcinoma - Pipeline by Cellceutix Corporation, H2 2016 38 Metastatic Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2016 39 Metastatic Renal Cell Carcinoma - Pipeline by Cerulean Pharma, Inc., H2 2016 40 Metastatic Renal Cell Carcinoma - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 41 Metastatic Renal Cell Carcinoma - Pipeline by EirGenix Inc., H2 2016 42 Metastatic Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2016 43 Metastatic Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2016 44 Metastatic Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H2 2016 45 Metastatic Renal Cell Carcinoma - Pipeline by Gene Techno Science Co., Ltd., H2 2016 46 Metastatic Renal Cell Carcinoma - Pipeline by Genor BioPharma Co., Ltd., H2 2016 47 Metastatic Renal Cell Carcinoma - Pipeline by Immune Design Corp., H2 2016 48 Metastatic Renal Cell Carcinoma - Pipeline by Immunicum AB, H2 2016 49 Metastatic Renal Cell Carcinoma - Pipeline by Incyte Corporation, H2 2016 50 Metastatic Renal Cell Carcinoma - Pipeline by Mabion SA, H2 2016 51 Metastatic Renal Cell Carcinoma - Pipeline by MedImmune, LLC, H2 2016 52 Metastatic Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2016 53 Metastatic Renal Cell Carcinoma - Pipeline by Merck KGaA, H2 2016 54 Metastatic Renal Cell Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 55 Metastatic Renal Cell Carcinoma - Pipeline by Mycenax Biotech Inc., H2 2016 56 Metastatic Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H2 2016 57 Metastatic Renal Cell Carcinoma - Pipeline by Novartis AG, H2 2016 58 Metastatic Renal Cell Carcinoma - Pipeline by Oncobiologics, Inc., H2 2016 59 Metastatic Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 60 Metastatic Renal Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2016 61 Metastatic Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H2 2016 62 Metastatic Renal Cell Carcinoma - Pipeline by Pfizer Inc., H2 2016 63 Metastatic Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H2 2016 64 Metastatic Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016 65 Metastatic Renal Cell Carcinoma - Pipeline by Richter Gedeon Nyrt., H2 2016 66 Metastatic Renal Cell Carcinoma - Pipeline by Seattle Genetics, Inc., H2 2016 67 Metastatic Renal Cell Carcinoma - Pipeline by Sevion Therapeutics, Inc., H2 2016 68 Metastatic Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals Inc, H2 2016 69 Metastatic Renal Cell Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 70 Metastatic Renal Cell Carcinoma - Pipeline by Tocagen Inc., H2 2016 71 Metastatic Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H2 2016 72 Metastatic Renal Cell Carcinoma - Pipeline by Tyrogenex, Inc., H2 2016 73 Assessment by Monotherapy Products, H2 2016 74 Assessment by Combination Products, H2 2016 75 Number of Products by Stage and Target, H2 2016 77 Number of Products by Stage and Mechanism of Action, H2 2016 85 Number of Products by Stage and Route of Administration, H2 2016 92 Number of Products by Stage and Molecule Type, H2 2016 94 Metastatic Renal Cell Carcinoma - Dormant Projects, H2 2016 351 Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..1), H2 2016 352 Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..2), H2 2016 353 Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..3), H2 2016 354 Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..4), H2 2016 355 Metastatic Renal Cell Carcinoma - Discontinued Products, H2 2016 356
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
